An analyst at Goldman Sachs thinks a coronavirus vaccine could be approved before year-end by the U.S. as the country tries to stem a massive uptick in cases.
Data compiled by Johns Hopkins University showed U.S. cases grew by a staggering 77,200 — shattering a one-day record. Cases are rising in nearly every state as authorities roll back social distancing measures. California, Florida and Texas are some of the hardest-hit states recently. On Thursday alone, they combined for more than 38,000 cases.
The virus’ rapid spread has led the U.S. government to fast track the development of a potential vaccine, leading Goldman analyst Salveen Richter to believe “a vaccine may gain US approval in 2H20.”
Below are some companies highlighted by Goldman Sachs that could get a vaccine candidate approved later this year.
Moderna released data earlier this week that showed all patients in an early trial received neutralizing antibodies after taking the company’s vaccine candidate. The news pushed Moderna shares up more than 40% this week.
“Management guided to potential for full phase 3 efficacy data (151 events) around Thanksgiving (11/26)/4Q20 – however, there are two interim reads at 53 and 106 events – which could enable earlier approval (pursuing a rolling submission; Fast Track designation),” Richter said in a note.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE